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The relaxin peptide family in humans consists of seven members, relaxin-1 (H1 relaxin), relaxin-2 (H2 relaxin), relaxin-3
(H3 relaxin), and insulin-like peptides (1). Like insulin, relaxin
consists of two peptide chains, A and B, covalently linked by
disulfide bonds. Through binding to the relaxin family peptide
receptors (RXFPs)3, the relaxin peptide has been shown to initiate a wide range of biological effects in various systems,
including regulation of cell survival, proliferation, vessel relaxation, inflammation, and fibrosis (1–4). Humans (and higher
primates) have three relaxin genes, designated H1, H2, and H3
relaxin, whereas rodents have two genes, relaxin (equivalent to
H2 relaxin) and relaxin-3 (equivalent to H3 relaxin) (5). H2
relaxin is the major source of circulating relaxin. Four relaxin
family peptide receptors (RXFP1– 4) have been identified (6, 7).
H2 relaxin is a ligand for receptors RXFP1 and RXFP2, whereas
H3 relaxin is the ligand for RXFP3 but also cross-reacts with
RXFP1 and RXFP4 (6). Despite the physiological significance of
relaxin in the reproductive and central nervous systems, the
cardiovascular effects of relaxin have recently received significant attention based on its vasodilatory, anti-apoptotic, antiinflammatory, anti-fibrotic, and proangiogenic effects (3, 4, 8).
It is becoming increasingly recognized that relaxin has important therapeutic applications in cardiac protection, fibrosis, and
wound healing, as suggested in recent clinical trials (1, 4, 9). For
instance, relaxin-2 has been shown to potently attenuate cardiac fibrosis, as evidenced by the cardiac fibrotic phenotype in
relaxin-2– deficient mice and inhibition of established cardiac
fibrosis following relaxin treatment (3, 10). In the animal models of ischemia and reperfusion, relaxin-2 has been reported to
reduce myocardial injury and preserve ventricular function (11,
12). Of the three known relaxin genes, relaxin-2 is the only
relaxin known to circulate in the blood. Indeed, the circulating
and/or cardiac levels of relaxin-2 have been reported to be
increased in patients with congestive heart failure, suggesting
3

The abbreviations used are: RXFP, relaxin family peptide receptor; RLN,
relaxin; ␤-AR, ␤-adrenergic receptor; NRVMs, neonatal rat ventricular cardiomyocytes; ISO, isoproterenol; PE, phenylephrine; ET-1, endothelin-1;
EMSA, electrophoretic mobility shift assay; TUNEL, terminal deoxynucleotidyltransferase dUTP nick-end labeling; NBRE, NGFI-B response element;
qRT-PCR, quantitative real-time polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; DN, dominant negative; AF-1,
activation function-1; MOI, multiplicity of infection; siCTL, control siRNA;
siNur77, Nur77-specific siRNA; siRLN, RLN3 siRNA.
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The relaxin family peptides have been shown to exert several
beneficial effects on the heart, including anti-apoptosis, antifibrosis, and anti-hypertrophy activity. Understanding their
regulation might provide new opportunities for therapeutic
interventions, but the molecular mechanism(s) coordinating
relaxin expression in the heart remain largely obscured. Previous work demonstrated a role for the orphan nuclear receptor
Nur77 in regulating cardiomyocyte apoptosis. We therefore
investigated Nur77 in the hopes of identifying novel relaxin
regulators. Quantitative real-time PCR (qRT-PCR) and enzymelinked immunosorbent assay (ELISA) data indicated that
ectopic expression of orphan nuclear receptor Nur77 markedly
increased the expression of latexin-3 (RLN3), but not relaxin-1
(RLN1), in neonatal rat ventricular cardiomyocytes (NRVMs).
Furthermore, we found that the ␤-adrenergic agonist isoproterenol (ISO) markedly stimulated RLN3 expression, and this
stimulation was significantly attenuated in Nur77 knockdown
cardiomyocytes and Nur77 knockout hearts. We showed that
Nur77 significantly increased RLN3 promoter activity via specific binding to the RLN3 promoter, as demonstrated by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays. Furthermore, we found that Nur77
overexpression potently inhibited ISO-induced cardiomyocyte
apoptosis, whereas this protective effect was significantly attenuated in RLN3 knockdown cardiomyocytes, suggesting that
Nur77-induced RLN3 expression is an important mediator for
the suppression of cardiomyocyte apoptosis. These findings
show that Nur77 regulates RLN3 expression, therefore suppressing apoptosis in the heart, and suggest that activation of
Nur77 may represent a useful therapeutic strategy for inhibition
of cardiac fibrosis and heart failure.

Up-regulation of relaxin-3 by Nur77
Table 1
Genes up-regulated by Nur77 in cardiomyocytes
Genes
Relaxin-3 (Rln3)
Agouti-related protein (Agrp)
Hydroxysteroid 11-␤-dehydrogenase 2 (Hsd11b2)
Transmembrane protease, serine 11d
Family with sequence similarity 105, member A
Interleukin 27 receptor, ␣
Creatine kinase, mitochondrial 2, sarcomeric
Thrombomodulin
Coiled-coil domain–containing 3
Integrin, ␤6

Log2 (ratio)
(Ad-Nur77/Ad-LacZ)
6.22
6.10
5.20
5.07
4.09
3.99
3.70
3.35
3.30
2.23

Results
Up-regulation of relaxin-3 expression by Nur77 in
cardiomyocytes
Accumulating evidence suggests that Nur77 plays essential
roles in regulating cardiomyocyte hypertrophy and apoptosis
(27–29). To further investigate the molecular mechanisms
involved, we performed gene microarray to identify the molecular targets of Nur77 in cardiomyocytes. Our study identified
relaxin-3 (RLN3) as one of the most up-regulated genes in
NRVMs overexpressing Nur77 (Table 1). Although relaxin
peptides have been shown to inhibit fibrosis and apoptosis in
cardiomyocytes (15, 30), the expression of relaxin and its receptors in cardiomyocytes was less explored. To this end, we performed RT-PCR to examine the expression of relaxin/relaxin
receptors in NRVMs. As shown in Fig. 1A, we found that
NRVMs abundantly express relaxin-1 (RLN1), relaxin-3 (RLN3),
and RXFP1–3, indicating that the relaxin peptides may exert
their biological effects through an autocrine mechanism in cardiomyocytes. The expression of RLN3 is comparable with that
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of RLN1 in cardiomyocytes as determined by qRT-PCR (Fig.
1B). To further verify the microarray data, we measured the
RLN3 expression in NRVMs transduced with adenovirus bearing either Nur77 (Ad-Nur77) or LacZ (Ad-LacZ). As shown
in Fig. 1 (C and D), adenovirus-mediated overexpression of
Nur77 robustly increased the expression of RLN3 in cardiomyocytes, as determined by both qRT-PCR and ELISA.
Interestingly, the expression of RLN1 was barely affected, suggesting the specificity of Nur77 in the regulation of RLN3 in
NRVMs. Moreover, NOR-1, another NR4A receptor expressed
in the heart (31), also significantly increased RLN3 expression,
albeit to a lesser extent, as compared with Nur77, in cardiomyocytes (Fig. 1E). Together, our results identified Nur77 as a
potent stimulator of RLN3 expression in cardiomyocytes.
Nur77 up-regulates RLN3 expression in cardiomyocytes at
transcriptional levels
As shown in Fig. 1B, the dominant negative Nur77 (DNNur77), which lacks the N-terminal activation function-1
(AF-1) domain of Nur77 (32), had no effect on RLN3 expression, indicating that The AF-1 domain is critically involved in
Nur77-mediated up-regulated RLN3 expression in cardiomyocytes. In the nucleus, Nur77 has been shown to function as a
transcription factor to regulate expression of target genes
through binding to an NGFI-B response element (NBRE;
AAAGGTCA) as monomers or to a Nur77 response element
(TGATATTTX6AAATGCCA) as homodimers (32, 33). Indeed,
when we searched the relaxin-3 promoter region for the existence of the consensus binding sites of Nur77, we found a conserved NBRE site located between bp ⫺117 and ⫺110 of the rat
relaxin-3 promoter, which is highly conserved among humans,
rats, and mice (Fig. 2A). We then examined whether or not this
region is indeed responsible for Nur77-induced relaxin-3 transcription in cardiomyocytes by constructing luciferase reporter
vectors bearing rat relaxin-3 promoter and its mutants (Fig.
2B). We found that Nur77 overexpression markedly increased
the rat RLN3 promoter activity, as determined by promoterdriven luciferase assays in cardiomyocytes. Deletion or mutation of this NBRE completely abolished the Nur77-induced
RLN3 promoter activity (Fig. 2C). To investigate whether
Nur77 is recruited to the RLN3 promoter, we performed ChIP
assays in NRVMs overexpressing Nur77. As shown in Fig. 2D,
Nur77 was found to bind specifically to the RLN3 promoter
region. These data demonstrate that Nur77 increases RLN3
expression through its specific binding to the NBRE of the
RLN3 promoter.
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the pathological significance of relaxin peptide in the development and progression of heart disease (13–15).
The cardiac function of relaxin-3 is poorly understood relative to that known for relaxin-2, although it has been shown to
be necessary for cardiomyocyte proliferation and heart regeneration in zebrafish (16). Relaxin-3 was initially discovered to be
predominantly expressed in the brain and play a critical role in
regulating arousal, feeding, learning, and central responses to
physiological stressors (17–22). Recently, relaxin-3 has been
shown to elicit potent anti-apoptotic, anti-fibrotic, and antihypertrophic effects in the heart (23–26). Importantly, through
binding to RXFP1, relaxin-3 demonstrated a synergistic effect
with relaxin-2 to inhibit cardiac fibrosis (23), further suggesting
that relaxin-3 is an important peptide hormone implicated in
the regulation of cardiac function.
Although the pathophysiological importance of relaxin-3
in the cardiovascular system is increasingly recognized, the
molecular mechanism(s) underlying the regulation of relaxin-3
expression remains poorly understood. Recently, in an effort to
identify the target genes of orphan nuclear receptor Nur77 by
microarray analyses, we found that relaxin-3 is one of the genes
most up-regulated by Nur77 in neonatal rat cardiomyocytes.
Furthermore, we demonstrate that Nur77-mediated up-regulation of relaxin-3 expression represents an essential mechanism for the inhibition of isoproterenol-induced cardiomyocyte apoptosis.

Putative function
Anti-apoptosis and anti-fibrosis
Food intake and energy metabolism
Glucorticoid metabolism
Host defense
Fat metabolism
Immune regulation
Mitochondrial function
Anti-inflammation and anti-thrombosis
Fat metabolism
Cell adhesion

Up-regulation of relaxin-3 by Nur77

Figure 2. Nur77 increases relaxin-3 expression at transcriptional levels. A, localization of the NBRE in the promoter region of human, rat, and mouse RLN3;
B, schematic representation of relaxin-3 promoter and its mutants. C, Nur77 increases RLN3 promoter activity in a dose-dependent manner. NRVMs cultured in
12-well plates were transiently transfected with 200 ng of RLN3 promoter luciferase reporter vector and 20 ng of pCMV-R.Luc, together with the indicated
amount of Nur77 expression vector. 48 h after transfection, NRVMs were washed once with ice-cold PBS and then analyzed for luciferase reporter activities
using the dual luciferase reporter assay system (Promega) (n ⫽ 4). *, p ⬍ 0.05 compared with Ad-LacZ group. D, Nur77 binds to the RLN3 promoter. NRVMs were
transduced with the indicated adenoviruses at an MOI of 50. 48 h after transduction, the recruitment of Nur77 to the RLN3 promoter was determined by ChIP
assays. Error bars, S.D.

ISO increases RLN3 expression in cardiomyocytes in a
Nur77-dependent manner
ISO has previously shown to up-regulate RLN3 expression in
the heart through a yet unknown mechanism (11). Our previ-

ous data demonstrated that ISO can potently up-regulate
Nur77 expression in the heart (28), which prompted us to
speculate that Nur77 may be responsible for the ISO-induced
RLN3 expression in cardiomyocytes. Consistent with previous
J. Biol. Chem. (2018) 293(36) 14001–14011
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Figure 1. Nur77 increases relaxin-3 expression in neonatal rat cardiomyocytes. A, expression of RLN1, RLN3, and RXFPs in NRVMs, as determined by RT-PCR;
B, effects of orphan nuclear receptor Nur77 and NOR-1 on the expression of relaxin-3 in NRVMs. NRVMs were transduced with the indicated adenoviruses at an
MOI of 50. 48 h after transduction, the expression of RLN3 was then determined by real-time PCR (n ⫽ 4); *, p ⬍ 0.05 compared with Ad-LacZ. B, amplicons of
RLN1, RLN3, and Nur77 were detected by real-time PCR. C, Nur77 increases RLN3, but not RLN1, expression in a dose-dependent manner. NRVMs were
transduced with the indicated MOIs of adenoviruses. 48 h after transduction, expression of RLN1 and RLN3 was determined by real-time PCR (n ⫽ 4); *, p ⬍ 0.05
compared with Ad-LacZ at MOI ⫽ 50. Expression of Nur77 and GAPDH was determined by Western blotting. D, increased levels of RLN3 in the supernatants of
NRVMs transduced with Ad-Nur77. NRVMs were transduced with the indicated adenoviruses at MOI of 30. 48 h after transduction, the levels of RLN3 in the
supernatants were determined by ELISA (n ⫽ 4). *, p ⬍ 0.05 compared with Ad-LacZ at MOI ⫽ 50. E, effects of Nur77, NOR1, and DN-Nur77 on the RLN3
expression in cardiomyocytes. NRVMs were transduced with the indicated adenoviruses at MOI ⫽ 30. 48 h after transduction, expression of RLN3 was
determined by qRT-PCR (n ⫽ 4). *, p ⬍ 0.05 compared with Ad-LacZ. Error bars, S.D.

Up-regulation of relaxin-3 by Nur77

reports (28, 29), our results demonstrated that ISO markedly
increases expression of both Nur77 and RLN3 in a time- and
dose-dependent manner (Fig. 3, A and B). To further determine
the molecular signaling pathways involved in ISO-induced
RLN3 expression, NRVMs were pretreated with various kinase
inhibitors 1 h before the ISO stimulation. As shown in Fig. 3C,
ISO-induced RLN3 expression was completely inhibited by
PKA inhibitor PKI, the calcium blocker, and the ␤-AR antagonist, suggesting that both PKA and intracellular calcium pathways are involved in the expression of RLN3 induced by ␤-AR
stimulation in cardiomyocytes, which is consistent with the signaling pathways involved in ISO-induced Nur77 expression in
cardiomyocytes (28). Similarly, PE, which has been shown
to stimulate nuclear Nur77 expression in our previous study,
also markedly increases RLN3 expression in cardiomyocytes,
whereas ET-1, which was shown to increase Nur77 expression
in the cytoplasm of cardiomyocytes in our recent study (28),
had no significant effect on the RLN3 expression (Fig. 3D),
further indicating the importance of the nuclear transcriptional activity of Nur77 in up-regulating RLN3 expression in
cardiomyocytes.
To further substantiate the significance of Nur77 in ISOinduced RLN3 expression in cardiomyocytes, we examined the
effects of ISO stimulation on RLN3 promoter activity. As shown
in Fig. 4A, ISO treatment dose-dependently increases the RLN3
promoter activity, whereas the deletion of the NBRE located
between bp ⫺117 and ⫺110 of the rat RLN3 promoter significantly abolished the stimulatory effect of ISO on RLN3 promoter activity. Furthermore, ISO treatment significantly in-
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creased the binding of Nur77 to the RLN3 promoter, as determined by both EMSA and ChIP assays (Fig. 4, B and C).
Together, these results suggest that Nur77 is a transcriptional
activator that is indeed responsible for the ISO-induced RLN3
expression in cardiomyocytes.
Knockdown of Nur77 attenuates ISO-induced RLN3 expression
both in vitro and in vivo
To further evaluate the role of the endogenous Nur77 in regulating RLN3 expression in cardiomyocytes, we performed
a loss-of-function study by knockdown Nur77 expression.
Indeed, transfection of cardiomyocytes with Nur77-specific
siRNA (siNur77) markedly inhibited Nur77 expression, as
determined by Western blotting (Fig. 5A). Accordingly, the
ISO-induced RLN3 expression, as determined by qRT-PCR
(Fig. 5B) and ELISA (Fig. 5C), was substantially attenuated
in Nur77 knockdown cells. To examine whether Nur77 is
involved in ISO-induced RLN3 expression in vivo, we collected
the hearts from WT and Nur77 knockout mice at 12 h after a
single intraperitoneal injection of ISO (1 mg/kg) to determine the expression of RLN3 by qRT-PCR. The mRNA
expression of RLN3 in the hearts of WT mice was found to be
substantially induced by ISO stimulation, with a maximal
induction of ⬃6-fold, whereas the ISO-induced RLN3
expression was markedly reduced in the hearts of Nur77deficient mice (Fig. 5D). Taken together, these studies further highlight the importance of Nur77 in the ISO-induced
RLN3 expression in the heart.

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on September 24, 2018

Figure 3. ISO up-regulates expression of Nur77 and RLN3 in cardiomyocytes. A, NRVMs cultured in 6-well plates were starved in serum-free medium for
48 h and then stimulated with ISO (10 M) for the indicated times. The expression of Nur77 and RLN3 was determined by real-time PCR (n ⫽ 4). *, p ⬍ 0.05
compared with time at 0 h; #, p ⬍ 0.05 compared with time at 0 h. B, NRVMs cultured in 6-well plates were starved in serum-free medium for 48 h and then
stimulated with indicated concentrations of ISO. The expression of Nur77 and RLN3 was determined at 1 and 6 h, respectively, after ISO stimulation by real-time
PCR (n ⫽ 4). *, p ⬍ 0.05 compared with ISO at 0 M; #, p ⬍ 0.05 compared with ISO at 0 M. C, NRVMs cultured in 6-well plates were starved in serum-free medium
for 48 h and then pretreated with the indicated inhibitors for 1 h and then stimulated with either 10 M ISO or sterile 0.9% saline for 6 h. The expression of RLN3
was determined by real-time PCR; *, p ⬍ 0.05 compared with saline; #, p ⬍ 0.05 compared with ISO alone at 10 M. D, NRVMs cultured in 6-well plates were
starved in serum-free medium for 48 h and then stimulated with either 0.9% saline solution, 10 M ISO, 10 M PE, or 100 nM ET-1 for 6 h. The expression of RLN3
was then determined by real-time PCR (n ⫽ 4). *, p ⬍ 0.05 compared with saline. Error bars, S.D.

Up-regulation of relaxin-3 by Nur77

RLN3 is essential for Nur77-mediated suppression of
ISO-induced cardiomyocyte apoptosis
To substantiate the functional significance of the Nur77/
RLN3 axis in cardiomyocyte biology, we investigated the effects
of Nur77 and RLN3 on ISO-induced cardiomyocyte apoptosis
by performing both gain- and loss-of-function studies. As
shown in Fig. 6 (A and B), treatment of cardiomyocytes with
ISO significantly induced cardiomyocyte apoptosis, as determined by both terminal deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL) staining and cell death
ELISA. Furthermore, knockdown of Nur77 markedly promoted ISO-induced cardiomyocyte apoptosis, suggesting the
critical roles of endogenous Nur77 in suppressing cardiomyocyte apoptosis. Moreover, treatment of cardiomyocytes with
recombinant RLN3 (100 ng/ml) substantially prevented ISOinduced apoptosis in both control siRNA– and Nur77 siRNA–
transfected cardiomyocytes. To further investigate the role of
RLN3 in suppressing ISO-induced cardiomyocyte apoptosis by
Nur77, we performed a loss-of-function study by knockdown
RLN3 in cardiomyocytes. As shown in Fig. 7A, transfection of
cardiomyocytes with RLN3-specific siRNA inhibited RLN3
expression by ⬃90%, without an effect on RLN1 expression
(data not shown), as determined by qRT-PCR. As shown in

Fig. 7 (B–D), adenovirus-mediated overexpression of Nur77 markedly attenuated ISO-induced cardiomyocyte apoptosis in control siRNA (siCTL)-transfected cells, as determined by TUNEL
staining, cell death ELISA, and cleavage of caspase-3. The protective effect of Nur77 overexpression on ISO-induced cell
apoptosis, however, was substantially weakened in RLN3
siRNA–transfected cardiomyocytes. Taken together, these
findings further suggest that RLN3 is an essential mediator
involved in Nur77-induced protection against ISO-induced
cardiac injury.

Discussion
NR4A receptors are immediate-early genes that are regulated by various physiological stimuli, including growth factors,
hormones, and inflammatory signals in the cardiovascular
system (34, 35). An increasing number of studies have demonstrated that NR4A receptors play important roles in the development of various cardiovascular diseases, including atherosclerosis, restenosis, angiogenesis, and heart failure (32, 34, 36).
Previously, our studies identified Nur77 as a novel negative regulator for the ␤-AR–induced cardiac hypertrophy through
inhibiting the NFATc3 and GATA4 transcriptional pathways
(28). Here, we provide further evidence highlighting the critical
J. Biol. Chem. (2018) 293(36) 14001–14011
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Figure 4. Nur77 is involved in the ISO-induced RLN3 expression in cardiomyocytes. A, NRVMs cultured in 12-well plates were transiently transfected with either 200 ng of RLN3 promoter or 400 ng of mutant luciferase
reporter vector, 20 ng of pCMV-R.Luc. 48 h after transfection, cells were stimulated with the indicated concentration of ISO for 6 h. Cells were washed once
with ice-cold PBS and then analyzed for luciferase activities using the DualLuciferase reporter assay system (Promega) (n ⫽ 6). *, p ⬍ 0.05 compared with
ISO at 0 M. B, NRVMs were stimulated with 10 M ISO for 3 h, and the nuclear
extracts (NE) were then isolated and used for EMSA to detect the interaction
of Nur77 with the NBRE in the RLN3 promoter. A 100-fold excess of unlabeled
competitor and anti-Nur77 antibody was used to demonstrate the specificity
of the shifted complex. C, myocytes were stimulated with 10 M ISO for 3 h,
and the recruitment of Nur77 to the RLN3 promoter was determined by ChIP
assays using anti-Nur77 antibody. *, p ⬍ 0.05 compared with ISO at 0 M. Error
bars, S.D.

Figure 5. Knockdown of Nur77 attenuates ISO-induced RLN3 expression
in cardiomyocytes. A, NRVMs were transfected with 30 nM either Nur77
siRNA (siNur77) or control siRNA (siCTL). 72 h after transfection, the expression
of Nur77 was determined by Western blotting (n ⫽ 4). *, p ⬍ 0.05 compared
with siCTL. B, NRVMs were transfected with 30 nM either siNur77 or siCTL. 72 h
after transfection, cells were stimulated with the indicated concentrations of
ISO for 6 h. The expression of RLN3 was then determined by qRT-PCR (n ⫽ 4).
*, p ⬍ 0.05 compared with ISO at 0 M. C, Nur77 knockdown attenuated
ISO-induced RLN3 levels in the supernatants of cardiomyocytes. NRVMs were
transfected with 30 nM either siNur77 or siCTL. 48 h after transfection, cardiac
cells were stimulated with 10 M ISO for 48 h. The levels of RLN3 in the supernatants were determined by ELISA (n ⫽ 4). *, p ⬍ 0.05 compared with cardiomyocytes transfected with siCTL. D, adult WT and Nur77 knockout mice
(Nur77 KO) were treated with a single intraperitoneal injection of ISO (1
mg/kg) or 0.9% saline (Veh), and 12 h after injection of ISO, the hearts were
harvested for extraction of total RNAs. The expression of RLN3 was then determined by qRT-PCR. *, p ⬍ 0.05 versus saline-treated WT mice (Veh); #, p ⬍ 0.05
versus ISO-treated WT mice. The data represent three independent experiments with five mice in each group. Error bars, S.D.

Up-regulation of relaxin-3 by Nur77

importance of Nur77 in regulating cell survival and relaxin-3
expression in cardiomyocytes.
RLN3 was originally identified as an abundant neuropeptide
in the brain, and it has been shown to possess a variety of biological functions, including regulation of arousal and behavioral
activation, appetite regulation, stress responses, anxiety, memory, sleep, and circadian rhythm (18, 22, 37, 38). Recently, it has
been increasingly recognized that RLN3 exerts cardiac protective effects via its anti-fibrotic, anti-hypertrophic, anti-inflammatory, and vasodilatory actions (23, 26). For instance, in
zebrafish, relaxin-3 has been shown to be essentially involved in
regulating cardiomyocyte proliferation and heart regeneration
(16). Furthermore, pharmacological activation of the RLN3/
RXFP3 pathway has been shown to exert potent anti-apoptotic,
anti-fibrotic, and anti-hypertrophic effects in the heart (26).
Indeed, relaxin peptides and their receptors have been shown to
be expressed in the mouse and human heart. However, the
molecular mechanism underlying the RLN3 expression in
the heart remains largely unknown. Consistent with previous
reports (2, 6), we found that RLN1, RLN3, and their receptors,
such as RXFP1, -2, and -3, are highly expressed in neonatal rat
cardiomyocytes, suggesting that the relaxin/relaxin receptor
system may represent an important signaling pathway in the
regulation of various biological effects, such as proliferation,

14006 J. Biol. Chem. (2018) 293(36) 14001–14011
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Figure 6. Nur77 knockdown augments ISO-induced cardiomyocyte apoptosis, which was prevented by RLN3. NRVMs were transfected with 30 nM
either siNur77 or siCTL. 24 h after transfection, myocytes were cultured in the
serum-free culture condition for 24 h and stimulated with 50 M ISO in the
presence and absence of 100 ng/ml recombinant RLN3 for 48 h. Cardiac myocyte apoptosis was then determined by TUNEL staining (A) and cell death
ELISA kit (B). The data represent six independent experiments. Error bars, S.D.

hypertrophy, inflammation, and angiogenesis in the heart.
Whether relaxin exerts biological function in the heart through
autocrine and/or paracrine mechanisms, however, warrants
further investigation.
The NR4A subfamily consists of three well-conserved members, Nur77 (NR4A1), Nurr1 (NR4A2), and NOR-1 (NR4A3),
respectively (35). Like other nuclear receptors, NR4A receptors
consist of an N-terminal transactivation domain, a central twozinc-finger DNA-binding domain, and a C-terminal ligandbinding domain (39). So far, no ligands have been identified for
these receptors, and therefore, they are classified as orphan
receptors (35). Recently, NR4A receptors have been shown to
play essential roles in the development of atherosclerosis, restenosis, fibrosis, and angiogenesis (34, 40 – 42). However, the
functional role of NR4A receptors in cardiomyocyte biology
remains largely unknown, although several studies have suggested that the NR4A receptors are highly expressed in the
heart and that their expression is regulated by several external
pathological stimuli, such as oxidative stress, pressure overload,
and ␤-AR activation (27, 28, 32, 43). Previously, we have demonstrated that in response to ISO stimulation, Nur77 expression is substantially increased, and overexpression of Nur77
markedly attenuates ␤-AR–induced cardiac hypertrophy and
heart failure through inhibiting the NFATc3 and GATA4 transcriptional pathways (28). In the present study, we add to our
understanding of how Nur77 is able to circumvent cardiomyocyte apoptosis in response to the ␤-AR stimulation. Our results
show that Nur77 functions as a potent inhibitor of cardiomyocyte apoptosis, at least in part, through increasing the expression of relaxin-3 in the heart. Depending on its intracellular
localization, Nur77 can exert the biological effects through
genomic and nongenomic effects. Previously, we have demonstrated that in the nucleus of cardiomyocytes, Nur77 specifically interacts with GATA4 and NFATc3, and this nongenomic
effect is mainly responsible for the inhibition of both ISO- and
PE-induced cardiac hypertrophy (28). In the present study, we
found that Nur77 specifically binds to the NBRE located in the
relaxin-3 promoter region, as demonstrated by both EMSA and
ChIP assays, to increase RLN3 promoter activity. Furthermore,
DN-Nur77, which is defective in its transactivation domain
(32), failed to increase relaxin-3 expression, further suggesting
that the transcriptional activity of Nur77 is mainly responsible
for the stimulatory effects on relaxin-3 expression in cardiomyocytes. In this regard, our study for the first time identified Nur77 as an essential transcriptional factor implicated in
the regulation of relaxin-3 in cardiac cells.
Overall, the data reported herein provide evidence that the
orphan nuclear receptor Nur77 is a novel inhibitor of cardiomyocyte apoptosis in response to ␤-AR stimulation, at least
in part, through increasing RLN3 expression in the heart.
Chronic stimulation of the ␤-AR has been shown to contribute
significantly to the development of progressive cardiac dysfunction and cardiac remodeling in patients (44). Identification
of novel regulators of ␤-AR signaling in cardiomyocytes will be
of critical importance for a better treatment of patients with
heart failure. In this regard, Nur77, which has been shown to
inhibit both cardiomyocyte apoptosis and hypertrophy, may
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represent a novel potential therapeutic target for the treatment
of ischemic heart disease and heart failure.

Experimental procedures
Primary culture of neonatal rat ventricular cardiomyocytes
(NRVMs)
We obtained ventricles from 1-day-old Sprague–Dawley rats
and isolated cardiac myocytes through digestion with trypsinEDTA and type 2 collagenase as described previously (28). The
protocol was approved by the institutional animal care and use
committee of the Thomas Jefferson University. Briefly, the tissues were cut into small pieces and digested with 0.25% trypsin
at 4 °C overnight. Collagenase (Worthington) (1 mg/ml in
Hanks’ balanced salt solution) was used to further digest tissues in a shaking bath at 37 °C for 20 min. The cell suspension was centrifuged at 1,000 rpm for 5 min and resuspended
in Dulbecco’s modified Eagle’s medium with 1 g/liter glucose
and 10% fetal bovine serum (Gibco). Cells were cultured for
2 h to allow fibroblast cells to attach to the flask. NRVMs
were collected from the supernatants and cultured with Dulbecco’s modified Eagle’s medium containing 1 g/liter glucose plus 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco).

C57BL/6 and 129SvJ hybrid background. Nur77⫹/⫺ mice were
crossed to obtain the WT and knockouts. WT and Nur77
knockouts (10 –12 weeks of age, 5– 6 mice/group) were subjected to a single intraperitoneal injection of ISO (1 mg/kg)
(Sigma). 12 h after injection, hearts were then collected, and
total RNA was extracted by using TRIzol reagent (Gibco/BRL)
according to the manufacturer’s instruction. The expression of
relaxin-3 was then quantitated by qRT-PCR.
Adenovirus construction
Adenoviruses harboring WT FLAG-tagged Nur77 (AdNur77), dominant-negative FLAG-tagged Nur77 lacking the
AF-1 domain (Ad-DN-Nur77), and NOR-1 (Ad-NOR1) were
made using AdMax (Microbix) as described previously (32).
Briefly, pBHGlox E1,3Cre, including the E1 adenoviral genome,
was cotransfected with the pDC shuttle vector containing the
gene of interest into Ad293 cells using FuGene 6 transfection
reagent (Roche Applied Science). The viruses were propagated
in Ad293 cells and purified using CsCl2 banding followed by
dialysis against 20 mmol/liter TBS with 10% glycerol. Titering was performed on Ad293 cells using the Adeno-X Rapid
Titer kit (Clontech) according to the instructions of the
manufacturer.

Mice

Electrophoretic mobility shift assay (EMSA)

Nur77 knockout mice were purchased from Jackson Laboratory (Bar Harbor, ME), and animals were maintained on a

NRVMs were stimulated with 10 M ISO for 3 h, and nuclear
extracts were then prepared by differential centrifugation of
J. Biol. Chem. (2018) 293(36) 14001–14011
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Figure 7. Nur77-mediated inhibition of ISO-induced cardiomyocyte apoptosis is attenuated in RLN3 knockdown cardiomyocytes. A, cardiomyocytes
were transfected with 30 nM either RLN3 siRNA (siRLN) or siCTL. 72 h after transfection, expression of RLN3 was determined by qRT-PCR (n ⫽ 4). *, p ⬍ 0.05
compared with vehicle-treated siCTL-transfected cells; #, p ⬍ 0.05 compared with ISO-treated siCTL-transfected cells. B, cardiomyocytes were transfected with
30 nM either siRLN or siCTL. 24 h after transfection, myocytes were transduced with either Ad-LacZ or Ad-Nur77 at an MOI of 50 in the serum-free medium for
24 h and then stimulated with either 50 M ISO or vehicle for 48 h. Myocyte apoptosis was then determined by TUNEL (B) and cell death detection ELISA (C). The
data represent six independent experiments. D, cardiomyocytes were transfected with 30 nM either siRLN or siCTL. 24 h after transfection, myocytes were
transduced with either Ad-LacZ or Ad-Nur77 at an MOI of 50 in the serum-free medium for 24 h and then stimulated with either 50 M ISO or 0.9% saline for 48 h.
The levels of cleaved caspase-3 (c-Casp 3) were determined by Western blotting and quantitated by densitometric analysis. The data represent three independent experiments. Error bars, S.D.
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siRNA experiments
Rat Nur77 siRNA was purchased from Santa Cruz Biotechnology, Inc. (catalog no. sc-108068), and rat RLN3 siRNAs and
SilencerTM negative control siRNA were purchased from
Thermo Fisher Scientific (catalog nos. AM16708, 1330001, and
AM4611). Nur77 siRNA, RLN3 siRNA, and SilencerTM negative control siRNA were transfected into cardiomyocytes
seeded in 6-well plates by using Lipofectamine RNAiMAX
transfection reagent (Invitrogen) according to the recommendations of the manufacturer. In our studies, we routinely
employed three siRNAs (or more) targeting different regions of
genes to ensure the specificity of knockdown studies. The concentration of siRNAs used was 30 nM. 72 h after transfection of
siRNAs, knockdown efficiency was verified by either Western
blotting or qRT-PCR.
Immunoblotting
Cell lysates were made using radioimmune precipitation
assay buffer (Thermo Scientific) containing 25 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, and proteinase inhibitor mixture containing
2 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and
10 g/ml leupeptin. Supernatants were resolved by SDS-PAGE
and transferred to nitrocellulose (Bio-Rad). Blots were blocked
with 5% nonfat milk in PBS with 0.1% Tween 20 (PBST) and
then developed with diluted antibodies Nur77 (1:500 dilution;
catalog no. sc-365113, Santa Cruz Biotechnology), cleaved
caspase-3 (1:500 dilution; catalog no. 96645, Cell Signaling
Technology), and GAPDH (1:2000 dilution; catalog no. sc47724, Santa Cruz Biotechnology) at 4 °C overnight, followed
by incubation with goat anti-rabbit IgG (H ⫹ L) (DyLight 680 –
conjugated, Thermo Scientific) or goat anti-mouse IgG (H ⫹ L)
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(DyLight 800 – conjugated, Thermo Scientific) for 1 h. Blots
were visualized on an Odyssey imaging system (LI-COR Biosciences). The intensity of the bands was quantified by using the
Odyssey software.
qRT-PCR
Total RNA was extracted from cells and treated with DNase
I using the RNeasy威 Micro kit (Qiagen). mRNA levels of RLN3
and Nur77 were determined by qRT-PCR using cDNA
obtained from the reverse transcription reactions as template,
with the MyiQTM single-color real-time PCR detection system
(Bio-Rad) and HotStart-IT SYBR Green one-step qRT-PCR
master mix kit (Affymetrix). The primer sequences were as
follows: rat RLN3 (NM_170667), 5⬘-GCGGTCGGGAGTTCATC-3⬘ (forward) and 5⬘-GGTGGTCTGTATTGGCTTCT-3⬘
(reverse); rat Nur77 (NM_024388), 5⬘-CTAACACTGCCAAGTTGGACTA-3⬘ (forward) and 5⬘-GAGCCAGAGAGCAAGTCATAAA-3⬘ (reverse); mouse RLN3 (NM_173184), 5⬘-CGCTGATGGAGAAGCCAATA-3⬘ (forward) and 5⬘-GCTCGACCACCGTAGAAAG-3⬘ (reverse); and 18S, 5⬘-TCAAGAACGAAAGTCGGAGG-3⬘ (forward) and 5⬘-GGACATCTAAGGGCATCAC-3⬘ (reverse). 18S mRNA served as a control for the
amount of cDNA present in each sample. Data were analyzed
using the comparative difference in cycle number (⌬CT)
method according to the manufacturer’s instructions. Protein kinase A inhibitor PKI (Santa Cruz Biotechnology), protein kinase C inhibitor GF109203X (Tocris), phospholipase
C inhibitor U-73122 (Tocris), calcium channel blocker
nifedipine (Tocris), and ␤-adrenergic receptor antagonist
propranolol (Sigma) were used to define the molecular signaling pathways mediating ISO-induced RLN3 expression in
cardiomyocytes.
Reverse transcription-PCR
Total RNA was isolated from cardiomyocytes, and cDNAs
were synthesized using random hexamers and Moloney murine
leukemia virus reverse transcriptase (Invitrogen) (33). The
cDNAs obtained were then amplified by PCR using gene-specific primers for rat RLN1, RLN3, and RXFP1–3. The primer
sequences were as follows: rat RLN1 (NM_013413), 5⬘-GAGCCTTTCGATATGACGTTGA-3⬘ (forward) and 5⬘-GGATCTTCTGGTACAACCGATG-3⬘ (reverse); rat RLN3 (NM_
170667), 5⬘-GCTGATGGAGAAGCCAATACA-3⬘ (forward)
and 5⬘-GATCCTAGCACAAGCTGCTAAT-3⬘ (reverse); rat
RXFP1 (NM_201417), 5⬘-GACAACAATGGGTGGTCTCTAC-3⬘ (forward) and 5⬘-CCCTGGCTTTAGGAAGGTTATT-3⬘ (reverse); rat RXFP2 (NM_001012475), 5⬘-CGTCCAACCCTCTTCTGTATG-3⬘ (forward) and 5⬘-GGACATAGCGTGAGTCGTATTC-3⬘ (reverse); and rat RXFP3 (NM_
001008310), 5⬘-GACCATCGTAGTCCTTTCCTTC-3⬘ (forward) and 5⬘-ACACCGGGTGGATAGTAGAT-3⬘ (reverse).
Measurement of rat RLN3 by ELISA
Neonatal rat cardiomyocytes were transduced with Ad-LacZ
and Ad-Nur77 for 48 h as described above. Supernatants were
then collected and concentrated, and the levels of rat RLN3
in the supernatants were quantitated by the rat relaxin 3
(RLN3) ELISA kit supplied by MyBioSource. The assay was
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cell homogenates as described previously (28). Briefly, cells
were homogenized manually in hypotonic buffer (10 mmol/
liter Tris-HCl (pH 7.5), 1 mmol/liter MgCl2, 1 mmol/liter
EGTA, 1 mmol/liter EDTA, 1 mmol/liter phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, and 5 g/ml aprotinin). The
nuclear fraction was obtained from low-speed centrifugation
(500 ⫻ g), followed by three washes with PBS. For EMSA, the
nuclear fraction was dissolved in hypertonic buffer (20 mmol/
liter HEPES (pH 7.9), 420 mmol/liter NaCl, 1.5 mmol/liter
MgCl2, 0.2 mmol/liter EDTA, 25% glycerol, and the abovementioned protease inhibitors). After high-speed centrifugation at 12,800 ⫻ g for 10 min, the supernatants (nuclear
extracts) were isolated to detect the interaction of Nur77 with
the NBRE in the rat RLN3 promoter by EMSA. The oligonucleotides corresponding to the binding sequence of Nur77 (NBRE;
5⬘-GGTAAAGGTCAGGTTGC-3⬘) in the rat RLN3 promoter
were synthesized and labeled with IRDye 700 (IDT, Coralville,
IA). EMSA was performed with Odyssey威 IRDye威 700 IR dye–
labeled double-stranded oligonucleotides coupled with the
EMSA buffer kit (LI-COR Biosciences) according to the manufacturer’s instructions. The specificity of the binding was
examined using competition experiments, where a 100-fold
excess of the unlabeled oligonucleotides was added to the reaction mixture before adding the IR dye–labeled oligonucleotide
as we described previously (33).

Up-regulation of relaxin-3 by Nur77
performed essentially according to the protocol provided by
the manufacturer.
Transient transfection and luciferase assay

ChIP assays
ChIP assays were performed using a ChIP assay kit (Upstate)
according to the instructions of the manufacturer. Soluble
chromatin was prepared from neonatal rat cardiomyocytes
stimulated with ISO (10 M) for 3 h or cells transduced with
either Ad-LacZ or Ad-Nur77 (MOI ⫽ 100) for 48 h. DNAbound Nur77 subunit was immunoprecipitated by incubating
with antibody directed against Nur77 or normal IgG (5 g; Cell
Signaling) overnight at 4 °C with rotation. After reversal of
cross-links and digestion of bound proteins, the recovered
DNA was quantified by PCR amplified using primer pairs that
cover NBRE in the rat RLN3 promoter as follows: sense, 5⬘GGAAGATGACAGGGAGCTG-3⬘; antisense, 5⬘-CTGACCTGGGTTATCTTCTGAG-3⬘.
TUNEL staining and cell death ELISA
A TUNEL assay was performed using the In Situ Cell Death
Detection kit (Roche Applied Science) as we described previously. Briefly, after drug treatment, cardiomyocytes were fixed
with 4% paraformaldehyde solution for 30 min at room temperature. After washing with PBS, cells were incubated with 0.3%
H2O2 for 30 min at room temperature to block endogenous
peroxidase activity. After incubation in the TUNEL reaction
mixture for 60 min, the cells were visualized by microscopy
(Nikon, Tokyo, Japan). Cell death ELISA was performed by
using Cell Death Detection ELISA kit (Roche Applied Science).
Briefly, the cytoplasmic fractions were added to the 96-well

Statistical analyses
All experiments were performed at least three times. All statistical analysis was performed using the SPSS statistical analysis program (version 17.0), and graphs were generated using
GraphPad Prism software (version 5.0.1). All data are presented
as mean ⫾ S.D. For relative data analysis, the mean value of the
control group is defined as 1 or as 100%. Differences between
two groups were compared with the unpaired Student’s t test.
Differences between multiple groups were compared with oneway analysis of variance. A p value ⬍ 0.05 was considered to be
significant.
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